Tucatinib in Breast Cancer: Maintenance Therapy Option
Okay, here’s a breakdown of the provided HTML snippet, focusing on its content and purpose. It appears to be a section of a news article from Healio,a medical news website,specifically related to oncology.
Overall Structure & Purpose
The code represents a portion of a news article about a study (HER2CLIMB-05) concerning the use of tucatinib in treating HER2-positive metastatic breast cancer. it includes:
- Email Alert Functionality: A section allowing users to subscribe to email alerts for topics related to the article.
- Article Content: The main body of the article, presenting the key findings and a quote from an expert.
- Article Footer: Information about the publisher, sources, references, and disclosures.
- Healio AI Component: A section promoting Healio’s AI features.
Detailed breakdown
* <i class="fas fa-plus-circle"/> Add topic to email alerts: This is an icon (using Font Awesome) and text that initiates the email alert subscription process. Clicking this would likely reveal the email-alert-inner div.
* <div class="email-alert-inner collapse u28d2294d0fa4426c844a5ae80ba5b81d">: This is a collapsible section (initially hidden, so “collapse”) that contains the email alert subscription form.
* <div class="email-alert-dialogue">: Contains the message explaining the alert. <span data-content="topic-title"/> is a placeholder that will be dynamically populated with the topic of the article.
* <div class="d-none" data-sign-up-type="unknown">: This section is initially hidden (d-none). It prompts the user to enter their email address.
* <button type="button" class="btn btn-primary" data-loading-text="Loading <i class="fa fa-spinner fa-spin">" data-action=subscribe>Subscribe</button>: The “Subscribe” button. It uses Bootstrap classes (btn, btn-primary) for styling.The data-loading-text attribute specifies the text to display while the subscription is processing (including a spinning spinner icon). data-action=subscribe indicates the action to be performed when the button is clicked.
* <div class="d-none" data-topic-modal="failed">: This section is initially hidden and displays an error message if the subscription fails. It also includes a button to return to the Healio website.
* <p>SAN ANTONIO - In this video, <b>He</b><b>o</b><b>Nora Teplinsky, MD</b><b>, </b>discusses results of the HER2CLIMB-05 study, showing that adding tucatinib to first-line maintenance therapy improved patient outcomes in HER2-positive metastatic breast cancer.</p>: The beginning of the article’s main content. it introduces the topic and the expert being quoted.
* <p>results of the trial, wich compared tucatinib (Tukysa, Seagen) with placebo in combination with trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta, Genentech), were presented at San Antonio Breast Cancer Symposium.</p>: Provides more details about the study.
* <p>"I think [tucatinib] will offer a great option as a maintenance approach for any patient with HER2-positive breast cancer, but notably in that hormone receptor-negative subtype," Teplinsky, head of breast and gynecologic medical oncology at Valley-Mount Sinai Comprehensive Cancer Care, told Healio.</p>: A direct quote from Dr. Teplinsky, providing her expert opinion.
* <div class="article__content--footer">: The footer section of the article.
* <div class="publisher-logo">: Displays the Healio logo.
* <div class="sources-references-disclosures">: Contains information about the article’s sources, references, and any relevant disclosures.
* <h2>source:</h2><p class="citation">Healio Interviews</p>: Indicates the source of the information.
* **`